Lilly to Acquire Novel CAR-T Innovator Orna Therapeutics for $2.4 Billion to Advance In Vivo Cell Therapy Platform
Eli Lilly has entered into a definitive agreement to acquire Orna Therapeutics, a biotechnology firm pioneering the development of immune cell therapies engineered directly within the body. The transaction is valued at up to $2.4 billion, including an upfront payment and milestone-based potential payouts. Also read: UCB presented long-term BE HEARD trial in patients with Hidradenitis Suppurativa Advancing In Vivo CAR-T and Genetic Medicine Orna Therapeutics is building a pi
EHSF 2026: UCB presented long-term BE HEARD trial in patients with Hidradenitis Suppurativa
UCB has released long-term BE HEARD trial data showing that bimekizumab (Bimzelx) delivered deep and durable improvements in hidradenitis suppurativa over three years, with results showcased at the European Hidradenitis Suppurativa Foundation (EHSF) 2026 meeting. The new analyses highlight bimekizumab’s capacity not only to clear inflammatory lesions but also to remodel disease severity categories and reduce structurally destructive draining tunnels over time. Long-term HS re
ACTRIMS 2026: Roche’s investigational therapy fenebrutinib shows breakthrough results in primary progressive multiple sclerosis (PPMS)
Roche has released new late-breaking Phase III data demonstrating that its experimental Bruton’s tyrosine kinase (BTK) inhibitor, fenebrutinib showing potential in patients with primary progressive multiple sclerosis (PPMS). Findings from the pivotal FENtrepid trial, presented at the ACTRIMS forum, indicate that fenebrutinib met its primary endpoint of non-inferiority to the current standard therapy, OCREVUS (ocrelizumab), in delaying disability progression among people with
FDA says no to AstraZeneca’s Saphnelo Subcutaneous Formulation for Lupus Patients | iPharmaCenter
The U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for AstraZeneca’s Biologics License Application (BLA) seeking approval of Saphnelo (anifrolumab) for subcutaneous administration in adults with systemic lupus erythematosus (SLE). This is despite Saphnelo SC meeting primary endpoint in clinical trial. AstraZeneca has provided the additional information requested and stated its commitment to working closely with the FDA to advance the appli
Top 10 Pharmaceutical Companies by Revenue 2025: Best-Selling Drugs Analysis | iPharmaCenter
Top pharmaceutical companies by revenues in 2025. The revenues are captured from the official websites of pharmaceutical companies
From $31.60 to $25: How New PBS Rules Make Prescriptions More Affordable
From 1 January 2026, Australians will pay less for many prescription medicines listed on the Pharmaceutical Benefits Scheme (PBS), with the maximum co-payment for Medicare card holders reduced from $31.60 to $25 per prescription. The concessional co-payment remains capped at $7.70 per script until 1 January 2030, helping to ease cost-of-living pressures for people on lower incomes. About the PBS and Co-payments The PBS, funded by the Australian Government, subsidises the cost